University of Groningen
Understanding individual drug response variation
Kroonen, Marjolein
DOI:
10.33612/diss.127010643
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Kroonen, M. (2020). Understanding individual drug response variation: Pharmacokinetic analysis of
diabetes trials. University of Groningen. https://doi.org/10.33612/diss.127010643
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Propositions
Belonging to the Thesis
Understanding individual drug response variation
Pharmacokinetic analysis of diabetes trials
1. When doses are properly adjusted, one can safely prescribe metformin to patients with impaired kidney function. (This thesis) 2. The variable response of various cardiovascular risk markers to
dapagliflozin is explained by the individual drug exposure. (This thesis)
3. Even when patients are prescribed the same dose of the same drug for the same disease, there is a large between-patient variability in drug exposure. (This thesis)
4. Exposure-response analysis are useful to perform to gain knowledge on an individual’s response, even though we do not know the site of action of the drug. (This thesis)
5. Individual drug exposure contributes to the between-patient variability in drug response. (This thesis)
6. Pharmacokinetic analysis should be integrated at an early phase in drug development and clinical trials.
7. Pharmacokinetic modelling can advance personalized medicine by individualizing optimal dosing regimens.
8. For clinical research you need a lot of patients/patience. 9. Absence of evidence is not evidence of absence. (John Locke) 10. All models are wrong, but some models are useful. (George E.P.
Box)
